Comparisons of Serum Sclerostin Levels among Patients with Postmenopausal Osteoporosis, Primary Hyperparathyroidism and Osteomalacia

 

 Buy Article Permissions and Reprints

Abstract

Wnt-β-catenin signaling is important for bone formation. Sclerostin inhibits bone formation mainly by suppressing this signal, and several studies suggest that the suppression of sclerostin expression contributes to the bone anabolic action of parathyroid hormone (PTH). We therefore examined serum sclerostin levels using enzyme-linked immunosolvent assay in 18 patients with postmenopausal osteoporosis, 9 postmenopausal women with primary hyperparathyroidism (pHPT) and 7 patients with osteomalacia. Serum levels of sclerostin were significantly lower in the group with pHPT, compared with those with postmenopausal osteoporosis. Moreover, serum sclerostin levels were significantly lower in the group with tumor-induced osteomalacia, but not in the group with osteomalacia without tumor, compared with those with postmenopausal osteoporosis. In patients with pHPT, serum sclerostin levels were significantly and negatively correlated to serum calcium and PTH levels. In patients with postmenopausal osteoporosis, serum levels of sclerostin levels were significantly and positively related to serum calcium and creatinine levels. In conclusion, we showed that serum sclerostin levels are decreased presumably through endogenous PTH elevation in postmenopausal women with pHPT, compared with the patients with postmenopausal osteoporosis.

References

• 1 Almqvist EG, Becker C, Bondeson AG. et al . Increased plasma concentrations of N-terminal pro-B-type natriuretic peptide in patients with mild primary hyperparathyroidism.  Clin Endocrinol. 2006;  65 760-766
  Google Scholar
• 2 Balemans W, Ebeling M, Patel N. et al . Increased bone density in sclerostosis is due to the deficiency of a novel secreted protein (SOST).  Hum Mol Genet. 2001;  10 537-543
  Google Scholar
• 3 Bando H, Hashimoto N, Hirota Y. et al . Severe hypophosphatemic osteomalacia with Fanconi syndrome, renal tubular acidosis, vitamin D deficiency and primary biliary cirrhosis.  Inter Med. 2009;  48 353-358
  Google Scholar
• 4 Bellido T, Ali AA, Gubrij I. et al . Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastgenesis.  Endocrinology. 2005;  146 4577-4583
  Google Scholar
• 5 van Bezooijen RL, Roelen BAJ, Visser A. et al . Sclerostin is an osteocyteexpressed negative regulator of bone formation, but not a classical BMP antagonist.  J Exp Med. 2004;  6 805-814
  Google Scholar
• 6 Canalis E. Update in new anabolic therapies for osteoporosis.  J Clin Endocrinol Metab. 2010;  95 1496-1504
  Google Scholar
• 7 Choi HY, Dieckmann M, Herz J. et al . Lrp4, a novel receptor for dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turn over in vivo.  Plos One 4. 2009;  4 e7930
  Google Scholar
• 8 Delfini E, Petramala L, Caliiumi C. et al . Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism.  Clin Exp Metab. 2007;  56 30-36
  Google Scholar
• 9 Drezner MK. Hypophosphatemic rickets.  Endocr Dev. 2003;  6 126-155
  Google Scholar
• 10 Endo I, Fukumoto S, Ozono K. et al . Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.  Bone. 2008;  42 1235-1239
  Google Scholar
• 11 Gaudion A, Pennisi P, Bratengeier C. et al . Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss.  J Clin Endocrinol Metab. 2010;  95 2248-2253
  Google Scholar
• 12 Grey A, Mitnick MA, Shapses S. et al . Circulating levels of interleukin-6 and tumor necrosis factor-a are elevated in primary hyperparathyroidism and correlate with markers of bone resorption – a clinical research center study.  J Clin Endocrinol Metab. 1996;  81 3450-3454
  Google Scholar
• 13 Hisa I, Kaji H, Inoue Y. et al . Fasting plasma glucose levels are related to bone mineral density in postmenopausal women with primary hyperparathyroidism.  Int J Clin Exp Med. 2008;  1 319-326
  Google Scholar
• 14 Hodsman AB, Bauer DC, Dempster DW. et al . Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.  Endocr Rev. 2005;  26 688-703
  Google Scholar
• 15 Inokuchi G, Tanimoto H, Ishida H. et al . A paranasal tumor associated with tumorinduced osteomalacia.  Laryngoscope. 2006;  116 1930-1933
  Google Scholar
• 16 Inoue Y, Canaff L, Hendy GN. et al . Role of Smad3, acting independently of transforming growth factor-β, in the early induction of Wnt-β-catenin signaling by parathyroid hormone in mouse osteoblastic cells.  J Cell Biochem. 2009;  108 285-294
  Google Scholar
• 17 Inoue Y, Kaji H, Hisa I. et al . Vitamin D status affects osteopenia in postmenopausal patients with primary hyperparathyrodism.  Endocr J. 2008;  55 57-65
  Google Scholar
• 18 Kaji H, Hisa I, Inoue Y. et al . Low density lipoprotein-cholesterol levels affect vertebral fracture risk in female patients with primary hyperparathyroidism.  Exp Clin Endocrinol Diabet. 2010;  118 371-376
  Google Scholar
• 19 Keller H, Kneissel M. SOST is a target gene for PTH in bone.  Bone. 2005;  37 148-158
  Google Scholar
• 20 Kramer I, Loots GG, Studer A. et al . Parathyroid hormone (PTH) – induced bone gain is blunted in SOST overexpression and deficient mice.  J Bone Miner Res. 2010;  25 178-189
  Google Scholar
• 21 Krishnan V, Bryant HU, MacDougald OA. Regulation of bone mass by Wnt signaling.  J Clin Invest. 2006;  116 1202-1209
  Google Scholar
• 22 Li X, Ominsky MS, Niu QT. et al . Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength.  J Bone Miner Res. 2008;  23 860-869
  Google Scholar
• 23 Li X, Ominsky MS, Warmington KS. et al . Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.  J Bone Miner Res. 2009;  24 578-588
  Google Scholar
• 24 Li X, Zhang Y, Kang H. et al . Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.  J Biol Chem. 2005;  280 19883-19887
  Google Scholar
• 25 Loots GG, Kneissel M, Keller H. et al . Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease.  Genomic Res. 2005;  15 928-935
  Google Scholar
• 26 Mirza FS, Padhi D, Raisz LG. et al . Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women.  J Clin Endocrinol Metab. 2010;  95 1991-1997
  Google Scholar
• 27 Nakchbandi IA, Lang R, Kinder B. et al . The role of the receptor activator of nuclear factor-kB ligand/osteoprotegerin cytokine system in primary hyperparathyroidism.  J Clin Endocrinol Metab. 2008;  93 967-973
  Google Scholar
• 28 Oka M, Kamo T, Sasaki E. et al . A case of phophateuric mesenchymal tumor (mixed connective tissue variant) that developed in the subcutaneous tissue of a patient with oncogenic osteomalaica and produced fibroblast growth factor 23.  Br J Dermatol. 2007;  157 198-200
  Google Scholar
• 29 Orimo H, Hayashi Y, Fukunaga H. et al . Diagnostic criteria of primary osteoporosis (2000 revision).  Jpan J Bone Miner Res. 2001;  18 76-82
  Google Scholar
• 30 Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.  J Biol Chem. 2005;  280 26770-26775
  Google Scholar
• 31 Swarthout JT, D’Alonzo RC, Selvamurugan N. et al . Parathyroid hormonedependent signaling pathways regulating genes in bone cells.  Gene. 2002;  282 1-17
  Google Scholar
• 32 Tobimatsu T, Kaji H, Sowa H. et al . Parathyroid hormone increases β-catenin levels through Smad3 in mouse osteoblastic cells.  Endocrinology. 2006;  147 2583-2590
  Google Scholar
• 33 White KE, Larsson TE, Econs MJ. The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23.  Endocr Rev. 2006;  27 221-241
  Google Scholar
• 34 Winkler DG, Sutherland MK, Geoghegan JC. et al . Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.  EMBO J. 2003;  22 6267-6276
  Google Scholar

Correspondence

H. Kaji

Division of Diabetes and

Endocrinology

Department of Internal

Medicine

Kobe University Graduate

School of Medicine 7–5–2

Chuo-ku Kobe 650-0017

Kusunoki-cho

Japan

Phone: + 81/72/382 5861

Fax: + 81/72/382 2080

Email: hiroshik@med.kobe-u.ac.jp